SRK-181-001 A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SRK-181 ADMINISTERED ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR IN PATIENTS

NCT04291079

A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SRK-181 ADMINISTERED ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (DRAGON)

Associated Conditions

Lung Cancer

Principal Investigator

Guru Sonpavde

Sponsor

Scholar Rock, Inc

The purpose of this study is to evaluate the safety and various biological effects of Study Drug SRK-181. This study will also evaluate whether or not SRK-181, given in combination with anti-PD-(L)1 antibody therapy, can help the immune system attack and kill tumors.

This study is currently enrolling.